Metagenics Acquires Symprove to Enhance Gut Health Portfolio

Metagenics, based in Aliso Viejo, California and backed by Gryphon Investors, has announced its acquisition of Symprove, a UK-based probiotic brand recognized as the number one choice among healthcare practitioners. The transaction, which was disclosed on January 22, 2026, aims to enhance Metagenics’ portfolio in the health and wellness sector, although specific financial terms were not revealed.

Symprove is known for its clinically proven, water-based probiotic formulation that addresses digestive issues and supports gut microbiome health. The brand’s unique delivery system allows live, active multi-strain bacteria to thrive in the gut, making it a preferred option for both consumers and healthcare professionals.

Ryan Fagan, Deal Partner at Gryphon Investors, which sponsors Metagenics, expressed enthusiasm about the acquisition, stating, “Symprove’s differentiated product is highly strategic for Metagenics’s portfolio of practitioner-recommended supplements.” He emphasized that the acquisition would enable Metagenics to enhance patient engagement and improve health outcomes globally.

Metagenics has a long-standing reputation for delivering high-quality, science-based nutritional supplements and medical foods. Founded in 1983, the company has established itself as a trusted brand in the health and wellness industry, particularly in the United States, where it is the top doctor-recommended professional supplement brand.

The acquisition aligns with Metagenics’ strategic goals of expanding its product offerings and market presence. Patrick Sly, CEO of Metagenics, remarked, “We are delighted to welcome Symprove to Metagenics. Its science-based, unique probiotic formulation centers on the gut microbiome – a core area for Metagenics.”

As part of the acquisition, Symprove will continue to operate under the leadership of CEO Will Bowler. Bowler noted, “After substantial growth during our partnership with bd-capital, becoming part of Metagenics is a great next step for Symprove as we look to scale and reach a wider market.”

In conjunction with this acquisition, Metagenics and Gryphon Investors completed a strategic debt recapitalization to ensure sufficient capital for ongoing investments in both organic growth and further acquisitions. This financial maneuver is expected to provide Metagenics with the resources necessary to pursue additional strategic opportunities.

Advisors for the transaction included Greenhill & Co. International LLP and Spayne Lindsay & Co. as financial advisors, while Kirkland & Ellis served as legal counsel. KPMG provided accounting and financial due diligence services. Jefferies, Stephenson Harwood, PwC, and OC&C acted as advisors to bd-capital.

Looking ahead, the integration of Symprove into Metagenics’ operations is anticipated to create synergies in product development and distribution, further solidifying Metagenics’ position in the competitive probiotic market.